Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21543027 | 0.82 | CNR2 (0.36) | CA2 | |
| SCHEMBL27145161 | 0.82 | CNR2 (0.36) | CA2 | |
| SCHEMBL2784044 | 0.82 | CNR2 (0.36) | CA2 | |
| SCHEMBL883447 | 0.77 | CA2 (0.43) | CA2 | |
| SCHEMBL8357912 | 0.77 | CA2 (0.43) | CA2 | |
| SCHEMBL5946041 | 0.75 | CA2 (0.31) | CA2 | |
| SCHEMBL4676064 | 0.74 | HIF1A (0.37) | CA2 | |
| SCHEMBL3556829 | 0.74 | HIF1A (0.37) | CA2 | |
| SCHEMBL11087412 | 0.73 | CA2 (0.31) | CA2 | |
| SCHEMBL1219001 | 0.72 | PDF (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3027615-B1 | ANTI-INFECTIVE COMPOUNDS | PASTEUR INSTITUT KOREA (KR) | 2021-07-21 | — | — | EP | disclosed |
| US-20160185774-A1 | Anti-Infective Compounds | INSTITUT PASTEUR KOREA (KR) | 2016-06-30 | — | — | US | disclosed |
| EP-3027615-A2 | ANTI-INFECTIVE COMPOUNDS | Institut Pasteur Korea (KR) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015014993-A2 | ANTI-INFECTIVE COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2015-02-05 | — | — | WO | disclosed |
| WO-2010001220-A1 | NEW 1,2,4-TRIAZINE DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | MUTABILIS SA (FR) | 2010-01-07 | — | — | WO | disclosed |
| EP-2141164-A1 | New 1,2,4-triazine derivatives and biological applications thereof | Mutabilis (FR) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185774-A1 | Anti-Infective Compounds | RABGGTB, ELANE, SERPINB1 | CA2 4703/4885TAS2R38 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.